$OSUR
OraSure Technologies Inc

2017 Q2 Form 10-Q Financial Statement

#000119312517252790 Filed on August 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $40.18M $31.36M
YoY Change 28.12% 3.2%
Cost Of Revenue $14.70M $10.27M
YoY Change 43.07% 6.0%
Gross Profit $25.48M $21.09M
YoY Change 20.83% 1.88%
Gross Profit Margin 63.41% 67.24%
Selling, General & Admin $15.25M $13.75M
YoY Change 10.92% -8.2%
% of Gross Profit 59.87% 65.22%
Research & Development $3.338M $2.985M
YoY Change 11.83% -0.37%
% of Gross Profit 13.1% 14.16%
Depreciation & Amortization $1.471M $1.388M
YoY Change 5.98% -3.61%
% of Gross Profit 5.77% 6.58%
Operating Expenses $18.59M $16.74M
YoY Change 11.08% -6.89%
Operating Profit $6.887M $4.349M
YoY Change 58.36% 59.83%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $96.00K -$340.0K
YoY Change -128.24% 257.89%
Pretax Income $6.983M $4.009M
YoY Change 74.18% 52.67%
Income Tax $1.555M $173.0K
% Of Pretax Income 22.27% 4.32%
Net Earnings $5.428M $3.836M
YoY Change 41.5% 94.92%
Net Earnings / Revenue 13.51% 12.23%
Basic Earnings Per Share $0.09 $0.07
Diluted Earnings Per Share $0.09 $0.07
COMMON SHARES
Basic Shares Outstanding 58.48M 55.54M shares
Diluted Shares Outstanding 60.73M 56.21M shares

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $160.2M $113.4M
YoY Change 41.27% 24.07%
Cash & Equivalents $104.9M $105.7M
Short-Term Investments $55.40M $7.700M
Other Short-Term Assets $1.027M $1.194M
YoY Change -13.99% 399.58%
Inventory $14.55M $11.37M
Prepaid Expenses $1.336M $1.942M
Receivables $26.73M $18.44M
Other Receivables $0.00 $0.00
Total Short-Term Assets $205.7M $146.4M
YoY Change 40.53% 16.85%
LONG-TERM ASSETS
Property, Plant & Equipment $20.29M $20.20M
YoY Change 0.45% 12.92%
Goodwill $19.48M $19.54M
YoY Change -0.3% -3.37%
Intangibles $9.343M $12.02M
YoY Change -22.27% -20.42%
Long-Term Investments
YoY Change
Other Assets $3.536M $1.784M
YoY Change 98.21% 11.57%
Total Long-Term Assets $52.65M $53.55M
YoY Change -1.67% -2.32%
TOTAL ASSETS
Total Short-Term Assets $205.7M $146.4M
Total Long-Term Assets $52.65M $53.55M
Total Assets $258.4M $199.9M
YoY Change 29.23% 11.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.623M $3.956M
YoY Change 143.25% -16.35%
Accrued Expenses $12.09M $8.293M
YoY Change 45.81% -7.49%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.19M $26.07M
YoY Change -11.04% 67.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $3.538M $2.018M
YoY Change 75.32% 60.41%
Total Long-Term Liabilities $3.538M $2.018M
YoY Change 75.32% 60.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.19M $26.07M
Total Long-Term Liabilities $3.538M $2.018M
Total Liabilities $26.73M $28.09M
YoY Change -4.84% 66.59%
SHAREHOLDERS EQUITY
Retained Earnings -$132.6M -$163.9M
YoY Change -19.1% -7.02%
Common Stock $374.0M $345.1M
YoY Change 8.37% -0.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $229.4M $168.8M
YoY Change
Total Liabilities & Shareholders Equity $258.4M $199.9M
YoY Change 29.23% 11.02%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income $5.428M $3.836M
YoY Change 41.5% 94.92%
Depreciation, Depletion And Amortization $1.471M $1.388M
YoY Change 5.98% -3.61%
Cash From Operating Activities $9.080M $12.00M
YoY Change -24.33% 278.55%
INVESTING ACTIVITIES
Capital Expenditures $689.0K $1.121M
YoY Change -38.54% 58.33%
Acquisitions
YoY Change
Other Investing Activities -$36.14M $0.00
YoY Change -100.0%
Cash From Investing Activities -$36.83M -$1.140M
YoY Change 3130.7% -75.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.24M 90.00K
YoY Change 12388.89% -181.82%
NET CHANGE
Cash From Operating Activities 9.080M 12.00M
Cash From Investing Activities -36.83M -1.140M
Cash From Financing Activities 11.24M 90.00K
Net Change In Cash -16.51M 10.95M
YoY Change -250.78% -763.64%
FREE CASH FLOW
Cash From Operating Activities $9.080M $12.00M
Capital Expenditures $689.0K $1.121M
Free Cash Flow $8.391M $10.88M
YoY Change -22.87% 341.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2008Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
25000000
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59459438 shares
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
3230000
CY2016Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105701000
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
637000
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12092000
CY2017Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
761000
CY2017Q2 us-gaap Assets Current
AssetsCurrent
205699000
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
26731000
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
804000
CY2017Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37709000
CY2017Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373964000
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9623000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
2312000
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59330000 shares
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2017Q2 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
3220000
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1477000
CY2017Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7833000
CY2017Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5410000
CY2017Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1305000
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11963000
CY2017Q2 us-gaap Assets
Assets
258351000
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
55354000
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
55409000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104872000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
106703000
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59330000 shares
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2017Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2209000
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6877000
CY2017Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16928000
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9343000
CY2017Q2 us-gaap Goodwill
Goodwill
19482000
CY2017Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9343000
CY2017Q2 us-gaap Inventory Net
InventoryNet
14548000
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
258351000
CY2017Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23192000
CY2017Q2 us-gaap Line Of Credit
LineOfCredit
0
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2187000
CY2017Q2 us-gaap Other Assets Current
OtherAssetsCurrent
1027000
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3536000
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3538000
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1336000
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20291000
CY2017Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1831000
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-132589000
CY2017Q2 us-gaap Short Term Investments
ShortTermInvestments
55354000
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
229412000
CY2017Q2 osur Taxes Payable Receivable Current And Noncurrent
TaxesPayableReceivableCurrentAndNoncurrent
1463000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94094000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
484000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11314000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
715000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
156441000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
56001000 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
56001000 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2016Q4 us-gaap Deferred Compensation Plan Assets
DeferredCompensationPlanAssets
1980000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1388000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2446000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7685000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
15197000
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
10337000
CY2016Q4 us-gaap Goodwill
Goodwill
18793000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19827000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
982000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
36067000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
350528000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4633000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14220000
CY2016Q4 us-gaap Assets
Assets
207935000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
11160000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
11160000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107959000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
109790000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10337000
CY2016Q4 us-gaap Inventory Net
InventoryNet
11799000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5366000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5399000
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1034000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207935000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17335000
CY2016Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1971000
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2143000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2331000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2304000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1722000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20033000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1831000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-150458000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
11160000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
185850000
CY2016Q4 osur Taxes Payable Receivable Current And Noncurrent
TaxesPayableReceivableCurrentAndNoncurrent
-39000
CY2015Q2 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
8600000
CY2015Q2 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
10400000
CY2015Q2 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
1800000
CY2015Q2 osur Contract Expiration Period
ContractExpirationPeriod
P3Y
dei Amendment Flag
AmendmentFlag
false
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1295000
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0
us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
55000
us-gaap Contracts Revenue
ContractsRevenue
0
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3087000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20126000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
26935000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-322000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2891000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.30
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
619000
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
dei Entity Registrant Name
EntityRegistrantName
ORASURE TECHNOLOGIES INC
dei Entity Central Index Key
EntityCentralIndexKey
0001116463
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
301000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-618000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-178000
us-gaap Gross Profit
GrossProfit
45787000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
12500000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14842000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23321000
us-gaap Income Taxes Paid
IncomeTaxesPaid
4325000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
83000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6923000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
713000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2680000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2047000 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5452000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4739000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1525000
us-gaap Line Of Credit Facility Collateral
LineOfCreditFacilityCollateral
Obligations under the Credit Agreement are secured by a first priority security interest in certain eligible accounts receivable, 65% of the equity of our subsidiary, DNAG, and certain related assets.
us-gaap Operating Expenses
OperatingExpenses
23029000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19805000
us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.00375 pure
us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2019-09-30
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-55000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-45215000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
21704000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
us-gaap Net Income Loss
NetIncomeLoss
17869000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
412000
us-gaap Operating Income Loss
OperatingIncomeLoss
22758000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2312000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6308000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
2108000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
563000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1209000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1567000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
62233000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
18585000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21014000
us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<p><em><u><font size="2">Deferred Revenue</font></u></em><i style="FONT-SIZE: 13px; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial">.</i>&#xA0;We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of June&#xA0;30, 2017 and December&#xA0;31, 2016 was comprised of customer prepayments of $1,477 and $1,388, respectively.</p>
us-gaap Revenue Recognition Sales Returns
RevenueRecognitionSalesReturns
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Customer Sales Returns and Allowances</u>.</i> We do not grant return rights to our customers for any product, except for our OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick<sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top">&#xAE;</sup> In-Home HIV product revenues in our consolidated statements of income. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of June&#xA0;30, 2017 and December&#xA0;31, 2016, the reserve for sales returns and allowances was $183 and $217, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product&#x2019;s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.</p> </div>
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-44000
us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
183000
us-gaap Revenues
Revenues
72722000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
70614000
us-gaap Share Based Compensation
ShareBasedCompensation
3631000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14379000
dei Trading Symbol
TradingSymbol
OSUR
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59755000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <i><u>Use of Estimates</u>.</i> The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies, accruals, and performance- based compensation expense, among others. These estimates and assumptions are based on management&#x2019;s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding, and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.</p> </div>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57708000 shares
osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
1234000
us-gaap Contracts Revenue
ContractsRevenue
6722000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11607000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9512000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
19050000
us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-782000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-17000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
15335000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
15335000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
209000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2729000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
16741000
us-gaap Operating Expenses
OperatingExpenses
34350000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3102000
us-gaap Net Income Loss
NetIncomeLoss
6282000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
287000
us-gaap Operating Income Loss
OperatingIncomeLoss
7048000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3230000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
7621000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-532000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3311000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2729000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12896000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6516000
us-gaap Income Taxes Paid
IncomeTaxesPaid
556000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
4083000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-893000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1452000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1949000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
647000 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
234000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2738000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.11
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
697000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.11
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-648000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-115000
us-gaap Gross Profit
GrossProfit
41398000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5351000
us-gaap Revenues
Revenues
60448000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
52827000
us-gaap Share Based Compensation
ShareBasedCompensation
2942000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16103000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56144000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55497000 shares
CY2017Q2 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
2600000
CY2015Q3 osur Additional Contract Revenue From Clinical And Regulatory Activities
AdditionalContractRevenueFromClinicalAndRegulatoryActivities
7200000
CY2016Q3 osur Remaining Contract Revenue From Clinical And Regulatory Activities
RemainingContractRevenueFromClinicalAndRegulatoryActivities
9600000
CY2016Q3 osur Maximum Contract Revenue From Clinical And Regulatory Activities
MaximumContractRevenueFromClinicalAndRegulatoryActivities
16600000
CY2016Q3 osur Initial Contract Revenue From Clinical And Regulatory Activities
InitialContractRevenueFromClinicalAndRegulatoryActivities
7000000
CY2016Q3 osur Contract Expiration Period
ContractExpirationPeriod
P6Y
CY2016 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
0
CY2016 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
217000
CY2017Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1862000
CY2016Q2 us-gaap Contracts Revenue
ContractsRevenue
3360000
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4199000
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
10274000
CY2016Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1388000
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2016Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-302000
CY2016Q2 us-gaap Gross Profit
GrossProfit
21085000
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6354000
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
4009000
CY2016Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
665000 shares
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
173000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
16736000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
3836000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
4349000
CY2016Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
363000
CY2016Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
3777000
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-340000
CY2016Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1121000
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2985000
CY2016Q2 us-gaap Revenues
Revenues
31359000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
27582000
CY2016Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7397000
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56208000 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55543000 shares
CY2017Q2 us-gaap Contracts Revenue
ContractsRevenue
0
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7235000
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
14699000
CY2017Q2 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0
CY2017Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1471000
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.09
CY2017Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-418000
CY2017Q2 us-gaap Gross Profit
GrossProfit
25477000
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7750000
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6983000
CY2017Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2250000 shares
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1555000
CY2017Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-55000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
18590000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
5428000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
6887000
CY2017Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
1044000
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000
CY2017Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
689000
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3338000
CY2017Q2 us-gaap Revenues
Revenues
40176000
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
39132000
CY2017Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7502000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60728000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
58478000 shares
CY2017Q2 osur Contract Revenues From Clinical And Regulatory Activities
ContractRevenuesFromClinicalAndRegulatoryActivities
590000

Files In Submission

Name View Source Status
0001193125-17-252790-index-headers.html Edgar Link pending
0001193125-17-252790-index.html Edgar Link pending
0001193125-17-252790.txt Edgar Link pending
0001193125-17-252790-xbrl.zip Edgar Link pending
d435147d10q.htm Edgar Link pending
d435147dex101.htm Edgar Link pending
d435147dex311.htm Edgar Link pending
d435147dex312.htm Edgar Link pending
d435147dex321.htm Edgar Link pending
d435147dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
osur-20170630.xml Edgar Link completed
osur-20170630.xsd Edgar Link pending
osur-20170630_cal.xml Edgar Link unprocessable
osur-20170630_def.xml Edgar Link unprocessable
osur-20170630_lab.xml Edgar Link unprocessable
osur-20170630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending